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Consumption has been a scourge of mankind since ancient times. This illness has charged a high price to
human lives. Many efforts have been made to defeatMycobacterium tuberculosis (Mt). TheM. tuberculosis
purine nucleoside phosphorylase (MtPNP) is considered an interesting target to pursuit new potential
inhibitors, inasmuch it belongs to the purine salvage pathway and its activity might be involved in the
mycobacterial latency process. Here we present the MtPNP crystallographic structure associated with
acyclovir and phosphate (MtPNP:ACY:PO4) at 2.10 Å resolution. Molecular dynamics simulations were
carried out in order to dissect MtPNP:ACY:PO4 structural features, and the inﬂuence of the ligand in the
binding pocket stability. Our results revealed that the ligand leads to active site lost of stability, in
agreement with experimental results, which demonstrate a considerable inhibitory activity against
MtPNP (Ki ¼ 150 nM). Furthermore, we observed that some residues which are important in the proper
ligand’s anchor into the human homologous enzyme do not present the same importance to MtPNP.
Therewithal, these ﬁndings contribute to the search of new speciﬁc inhibitors for MtPNP, since pecu-
liarities between the mycobacterial and human enzyme binding sites have been identiﬁed, making
a structural-based drug design feasible.
 2011 Elsevier Masson SAS. Open access under the Elsevier OA license.1. Introduction
Tuberculosis (TB) resurged in the late 1980s, and the World
Health Organization has declared it as a global emergency. TB
causes 9.4 million new infections and kills almost two million
people a year, standing behind, among infectious diseases, only to
AIDS [1]. It is estimated that one-third of the world’s population
(approximately two billion individuals) is infected with Mycobac-
terium tuberculosis (Mt). About 5e10% of the infected individuals
develop active TB during lifetime, as a result of latent infection
reactivation. However, the risk of developing the disease to those
co-infected with the human immunodeﬁciency virus (HIV)
increases to 5e15% annually. The high susceptibility of HIV infected619-900, Porto Alegre e RS,
zevedo Jr.), diogenes@pucrs.br
nder the Elsevier OA license.people to TB and the proliferation of multidrug-resistant strains
have created aworldwide interest in expanding current TB research
programs. New antimycobaterial agents are needed to confront
M. tuberculosis strains resistant to existing drugs and to shorten the
treatment course in order to improve patient’s compliance [2,3].
Homologue enzymes in the purine salvage pathway have been
identiﬁed in the M. tuberculosis genome sequence [4]. Purine
nucleoside phosphorylase (PNP), a component enzyme of this
pathway, was identiﬁed to play a central role in purine metabolism.
The salvage pathway represents an essential cellular process that is
crucial for many organisms, and its proteins could be implicated in
mycobacterial latency [5]. Thereby, PNP might represent an
attractive molecular target and offer an opportunity to overcome
this illness. In M. tuberculosis, this enzyme (MtPNP) is responsible
for catalyzing the reversible phosphorolysis of N-glycosidic bonds
of purine (deoxy)ribonucleosides, except adenosine, in the pres-
ence of inorganic phosphate (PO4), to generate (deoxy)ribose
1-phosphate and the corresponding purine base [6e10]. It is
R.A. Caceres et al. / Biochimie 94 (2012) 155e165156speciﬁc for purine nucleosides in the b-conﬁguration and cleaves
the glycosidic bond with inversion of conﬁguration to produce a-
(deoxy)ribose 1-phosphate [11].
Potent inhibitors of PNP from different sources are frequently
structural analogues of nucleoside substrates, base and/or pentose
moietymodiﬁcations. Nevertheless the development of new potent
selective inhibitors for MtPNP is still a scientiﬁc endeavor as they
may present high toxicity, thereby becoming inappropriate for
human administration. Accordingly, efforts to develop drugs with
selective toxicity based on structural differences between MtPNP
and thehumanhomologue (HsPNP) should bepursued. A numberof
research groupshave dedicated their efforts to determine speciﬁcity
of substrates, kinetic mechanisms, and three-dimensional struc-
tures for PNPs from different bacterial sources [12e20] in compar-
ison to HsPNP. Even though PNP activity is shared between humans
and M. tuberculosis, drugs with selective toxicity against the myco-
bacterial enzyme can still be developed if one takes advantage of
singular features that make them dissimilar [21].
The 9-(2-hydroxy-ethoxy-methyl)guanine, also known as
acyclovir (ACY) (Fig. 1), is a synthetic nucleoside analogue with a 9-
substituent acyclic chain, and is an useful clinical antiherpetic agent
that has been employed as a HsPNP inhibitor with moderate
activity in erythrocytes (Ki ¼ 91 mM) [22].
In accordance with this statement, this work describes the
crystallographic structure of MtPNP associated with ACY, which can
be a possible MtPNP inhibitor. Molecular dynamics (MD) simula-
tion was also performed in order to provide an insight into its
complex behavior under solution, giving valuable information
around the MtPNP atomic features. The principal component
analysis (PCA) was assessed through MD, aiming to extract the
preponderant movements and, consequently, analyze the confor-
mational changes when comparing the structure in the free form
and complexed with ACY. Furthermore, all these analysis can
support bases for a greater knowledge concerning this enzyme,
providing new insights into its active site, and might guide future
efforts to design selective and potential inhibitors for the myco-
bacterial enzyme, based on the structure of ACY.2. Materials and methods
2.1. Crystallization and data collection
MtPNP:ACY:PO4 was crystallized using the experimental
conditions described elsewhere [13,19]. PNP solution was concen-
trated to 25 mg/mL and co-crystallized with ACY. Hanging drops
were prepared by mixing 1 mL of protein solution and 1 mL ofFig. 1. Molecular formula of acyclovir.reservoir solution (100 mM Tris pH 8.0 25% PEG3350 25 mM
MgCl2). The crystal was ﬂash frozen at 100 K. X-ray diffraction data
were collected at 1.427 Å wavelength using Synchrotron Radiation
Source (Laboratório Nacional de Luz Síncrotron, Campinas e SP,
Brazil) and a CCD detector (MARCCD). The crystal diffracted at
2.10 Å and the data were processed using Mosﬂm, and scaled with
the Scala [23] programs.
2.2. Structure resolution and reﬁnement
The crystal structure of MtPNP:ACY:PO4 was determined by
standardmolecular replacement using theAMoRe software [24] and
the structure of MtPNP complexedwith 9-deazahypoxanthine (PDB
code: 1I80 [19]) as a template. Structure reﬁnement was performed
using the Refmac5 software [23]. The atomic positions obtained
from molecular replacement were used to initiate the crystallo-
graphic reﬁnement. The overall stereochemical quality of the ﬁnal
model was assessed by the Procheck software [25].
2.3. Molecular dynamics simulation protocol
MD simulations were performed with the MtPNP trimeric struc-
ture to provide a more realistic analysis, since this enzyme is bio-
logically active as a trimer [13,19]. Two systems were built, the ﬁrst
composed by MtPNP apoenzyme (the PO4 ions and ACY were
removed from the crystallographic structure), and the second by
MtPNP, PO4 ion, and ACY (MtPNP:ACY:PO4). The homotrimeric
structures provide a remarkable analysis possibility, since the
systematic association of each ligand on each monomer leads to
speciﬁc conformational changes in the same structure. Based on this,
in monomer B, the PO4 ion, and in monomer C, the PO4 ion and ACY,
were retrieved, allowing the evaluation of the inﬂuence of ACY and
PO4 to the conformational changes. TheMD simulationswere carried
out in periodic boundary conditions using Gromacs 4.0.5 [26,27]
package with Gromos 96.1 (53A6) force ﬁeld [28]. The molecular
topologyﬁle and forceﬁeldparameterswere generatedby theProdrg
program [29] except the ACY charges. The ACYpartial atomic charges
were determined by using the ChelpG method [30], implemented in
the Gaussian W03 program [31], at DFT/B3LYP/6-31G** level. Before
the MD simulations, the structures were solvated with the explicit
SPC/E water model [32] embedded in 79.56 Å  73.82 Å  52.14 Å
cubic box, in which the minimum distance between the protein
surface and the box face was 10 Å in both cases. The simulation
systems were composed of 31,121 (MtPNP) and 31,102 (MtPNP:A-
CY:PO4) water molecules. In both systems, Naþ counter ions were
added using Genion program of the Gromacs simulation suite to
neutralize the negative charge density of these systems.
The systemswere then submitted to a steepest descent followed
by conjugated gradient energyminimization down to a tolerance of
1000 kJ/mol, step by step. The entire systems were minimized to
remove close van der Waals contacts followed by a short MD
simulationwith position restrains for a period of 20 ps. Each system
was heatedwith gradual increments in the following temperatures:
100 K (10 ps), 150 K (10 ps), 200 K (10 ps), 250 K (10 ps), and 300 K
(10ps). Thereafter, the temperaturesof the systemswere adjusted to
310 K, and the velocities at each step were reassigned according to
the MaxwelleBoltzmann distribution. The temperatures of solvent
and solutes (MtPNP, ACY, and PO4) were independently coupled to
a thermal bath with a relaxation time of 0.1 ps using a velocity
rescale thermostat [33]. The pressure in the systems was weakly
coupled to a pressure bath of 1 atm by applying an isotropic scaling
and 0.5 ps relaxation time using the Berendsen barostat [34].
Afterwards, full MDs without restrains were carried out. These
were performed under normal temperature (310 K) and pressure
(1 bar) using a temperature coupling time constant of 0.1 ps and
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isothermal compressibility was set to 4.5  105 bar1 for water
simulations. All bond lengths, including hydrogen atoms, were
constrained by the LINCS algorithm [35]. The electrostatic interac-
tions were calculated by using the Particle mesh Ewald algorithm
[36], with interpolation order of 4 and a grid spacing of 1.2 Å. The
cutoff for van der Waals interactions was 14 Å. All simulations were
performed for 20 ns with a time step of 2 fs, and coordinates were
saved every 0.5 ps. All systems were simulated in NPT ensemble.
All analyses were performed on the ensemble of system
conﬁgurations extracted at 0.5 ps time intervals from the simula-
tion. The convergence of both simulations was analyzed in terms of
the secondary structure, root mean-square deviation (RMSD) from
the initial model structures, and radius of gyration (RG). The MD
simulation and analyses were performed in a DuoQuad Core 550
Xeone3.00 GHz server. Examinations and repairs of the molecular
structures were achieved using the Swiss PDBViewer v4.0 [37],
VMD [38], and PyMOL [39] programs. Analyses were performed
using the features within the GROMACS package.
2.4. Principal component analysis
Protein functions are embedded in their structure and a major
goal of protein simulation is to generate enough conﬁgurations of
the system of interest to extract functionally relevant motions. One
such tool for reducing the generateddimensionality ofMD trajectory
to an essential subspace encompassing few degrees of freedom,
eliminating the positional ﬂuctuations, is PCA [40], which is
a method commonly used for dissecting the dynamics of proteins
and their importance in biological processes, like protein folding or
substrate binding. The PCA analysis is a technique that reduces the
complexity of the data and extracts the concerted motion in simu-
lations that are essentially correlated and presumably meaningful
for biological function [41]. In the PCA analysis, a variance/covari-
ance matrix was constructed from the trajectories after removal of
the rotational and translational movements. A set of eigenvectors
and eigenvalues was identiﬁed by diagonalizing the matrix. The
eigenvalues represented the amplitudeof the eigenvectors along the
multidimensional space, and the displacements of atoms along each
eigenvector showed the concerted motions of protein along each
direction. An assumption of PCA analysis is that the correlated
motions for the function of the protein are described byeigenvectors
with large eigenvalues. The protein movements in the essential
subspace were identiﬁed by projecting the Cartesian trajectory
coordinates along the most important eigenvectors from the anal-
ysis. PCA was performed using analysis tools from the GROMACS
package, considering only the backbone atoms for generating the
covariance matrix. Prior to performing PCA, all translations and
rotational motions were eliminated by ﬁtting the trajectory to
a reference structure, in this case, the average structure.
2.5. Experimental materials
All chemicals were of analytical or reagent grade and were used
without further puriﬁcation. Inosine and ACY were acquired from
Sigma. Recombinant MtPNP was expressed and puriﬁed as previ-
ously described [14]. The steady-state activity assays were carried
out in a UV-2550 UVevisible Spectrophotometer and the ﬂuores-
cence binding assays were carried out in an RF-5301PC Spectro-
photometer, both from Shimadzu.
2.6. Enzyme activity assays
All enzyme activity assays were carried out under initial rate
conditions at 25 C in 100 mM Hepes pH 7.0 (500 mL total reactionvolumes), and each individual datum is the average of duplicate or
triplicate measurements. The phosphorolysis of Inosine to Hypo-
xanthine ( 3¼ 1000 M1 cm1 at 280 nm), in the presence of PO4
and MtPNP, was monitored spectrophotometrically by a time-
dependent decrease in absorbance [14]. In order to evaluate its
inhibitory effect, the concentration of ACY that reduces enzyme
activity by half (IC50) was determined by measuring initial velocity
rates at Inosine (40 mM) and PO4 (600 mM) concentrations close to
their KM values [14] in either absence or presence of ACY
(12e40 mM). The inhibition pattern was determined by measuring
initial velocity rates at varying Inosine concentrations
(20e600 mM), a ﬁxed non-saturating PO4 concentration (600 mM),
and ﬁxed-varying inhibitor concentrations (0e48 mM). For both
inhibition experiments, reactions were initiated by the addition of
MtPNP (55 nM) into the reaction mixture.
2.7. Fluorescence spectroscopy
Fluorescence titration of MtPNP by ACY was carried out at 25 C
by making microliter additions of 0.5 mM and 2.0 mM ACY stock
solutions (ﬁnal concentration ranging from 0.25 to 178.41 mM) to
2 mL of 3 mMMtPNP in 100 mM Hepes pH 7.0, keeping the dilution
to a maximum of 10.0%. Measurements of intrinsic protein ﬂuo-
rescence of MtPNP employed excitation wavelength at 290 nm and
emission wavelength ranging from 320 to 400 nm (maximum
lEM ¼ 334 nm). The slits for excitation and emission wavelengths
were, respectively, 15 and 1.5 nm. To account for the inner ﬁlter
effect due to ACY absorption of excitation light, two cuvettes were
placed in series so that the contents of the ﬁrst cuvette (either
buffer or ACY) acted as a ﬁlter of the excitation light and the light
from the second cuvette detected.
2.8. Experimental data analysis
The kinetic parameter values and their respective standard
errors were obtained by ﬁtting the data to the appropriate equa-
tions by using the nonlinear regression function of SigmaPlot 2004
(SPSS, Inc.). Data obtained in the inhibition pattern studies were
properly ﬁtted to Eq. (1), which describes a competitive inhibition,
where v is the measured reaction velocity, V is the maximal
velocity, A is the substrate concentration (either Inosine or PO4), Ka
is the substrate’s Michaelis constant, I is the inhibitor concentra-
tion, and Kis is the slope inhibition constant.
v ¼ VA=½Kað1þ I=KisÞ þ A (1)
Data from equilibrium ﬂuorescence spectroscopy were ﬁtted to
Eq. (2), the Hill equation [41], in which F is the observed ﬂuores-
cence signal, Fmax is the maximal ﬂuorescence, F/Fmax ratio is the
degree of saturation, n represents the total number of binding sites,
and K0 is the mean dissociation constant for MtPNP:ACY binary
complex formation, which is comprised of interaction factors and
the intrinsic dissociation constant.
F=Fmax ¼ An=ðK 0 þ AnÞ (2)
3. Results and discussion
3.1. Molecular replacement and crystallographic reﬁnement
The MtPNP:ACY:PO4 structure was solved by molecular
replacement with the AMoRe software [24] using the crystallo-
graphic structure of MtPNP complexed with 9-deazahypoxanthine
(PDB code: 1I80 [19]) as a template. The crystal diffracted at 2.10 Å
Table 1
Data collection and reﬁnement statistics. Values in parentheses refer to the highest
resolution shell.
X-ray wavelenght (Å) 1.427
Temperature (K) 100
Resolution range (Å) 33.94e2.10 (2.15e2.10)
Number of measurements with >2s (I) 288832
Number of independent reﬂections 31716
Space group P21212
Matthews coefﬁcient (Å3 Da1) 1.63
Unit-cell parameters
a (Å) 105.177
b (Å) 135.759
c (Å) 41.434
a ¼ b ¼ g () 90
Highest Resolution Shell (Å) 2.10
Data completeness (%) 93.92
Rsym (%)a 5.80
Rfactor (%)b 18.30
Rfree (%)c 26.20
Number of ligands 3
Number of phosphate groups 3
Number of water molecules 435
Observed RMSD from the ideal geometry
Bond lenghts (Å) 0.02
Bond angles () 2.39
B-factor values (Ǻ)2 d
Average B value for main chain 22.47
Average B values for side chain 23.36
Average B values for acyclovir 34.30
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building was performed with the MIFiT 3.1.0 program [42] using
Fobs  Fcalc and 2Fobs  Fcalc density maps that show the electron
density for ACY and PO4 in the structure (Fig. 2B). Atomic coordi-
nates for ACY and PO4 ions have been included in the model and all
crystallographic reﬁnement using Refmac5 [23] continued with
maximum likelihood protocol, followed by alternate cycles of
positional reﬁnement and manual rebuilding using MIFit 3.1.0 [42].
A total of 388 water molecules were added to the model. The ﬁnal
model had Rfree and Rfactor of 26.20% and 18.30%, respectively, and
a correlation coefﬁcient of 94.6%. The highest magnitude of the
correlation coefﬁcient function obtained for the Euler angles were
a ¼ 79.81, b ¼ 10.83, and g ¼ 183.84. The fractional coordinates
are Tx ¼ 0.0821, Ty ¼ 0.3041, and Tz ¼ 0.4043.
Data collection and structure reﬁnement are summarized in
Table 1. The Matthews coefﬁcient (Vm) is 1.63 Å3 Da1 assuming
a trimer for the asymmetric unit and 24.55% of solvent content.
Analysis of Ramachandran diagram 4ej for the structure indi-
cates that 89.10% of the residues are in the most favored regions,
9.50% in the additional allowed regions, 0.80% in the generously
allowed regions, and 0.60% in the disallowed regions of the plot.
Analysis of the electron density map (2Fobs  Fcalc) agrees with the
Thr209 of the three monomers, positioning this same residue in
the disallowed regions in the other MtPNP structure previous
solved [43].Average B values for phosphate groups 47.35
Average B values for waters 25.54
Ramachandran Plot
Residues in most favored regions (%) 89.10
Residues in additionally allowed regions (%) 9.50
Residues in generously allowed regions (%) 0.80
Residues in disallowed regions (%) 0.60
a Rsym ¼ 100
PjI(h)e<I(h)>/PI(h) with I(h), observed intensity and {I(h)}, mean
intensity of reﬂection h overall meansurement of I(h).
b Rfactor ¼ 100 
PjFobs  Fcalcj/
P
(Fobs), the sums being taken overall reﬂections
with F/s(F) > 2 cutoff.
c Rfree ¼ Rfactor for 10% of the data, which were not included during crystallo-
graphic reﬁnement.
d B values ¼ average B values for all non-hydrogen atoms.3.2. Crystallographic structure of MtPNP:ACY:PO4
The MtPNP:ACY:PO4 structure follows the same fold as other
MtPNPs described elsewhere [13,19,20,43]. The active sites of all
known trimeric PNPs are located near the subunit interfaces, and
there is one active site for each monomer near the subunit
interfaces.
The data obtained from crystallography revealed that the
structure is a trimer in the asymmetric unit (Fig. 3), like in solution
[13,19], and each monomer displays an a/b fold consisting ofFig. 2. (A) MtPNP monomer presented as cartoon; (B) MtPNP:ACY:PO4 2Fobs  Fcalc electron density map contoured at 1s; and (C) Classical MtPNP binding site presented as cartoon,
and the residues Glu189, Asn231, and ACY as sticks.
Fig. 3. Homotrimeric MtPNP:ACY:PO4 schematic drawing. The MtPNP is presented as
cartoon, and the ACY and PO4 as sticks.
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the electron density maps at ﬁnal stages of the crystallographic
reﬁnement shows that the ligand (ACY) is positioned into the
MtPNP classical binding site (Fig. 2C) anchored by the two binding
pocket main residues (Glu189 and Asn231). Each active site
contains one PO4 and one ACY molecule.Table 2
Hydrogen bonds and hydrophobic contacts of MtPNP:ACY:PO4 monomers during MD sim
MtPNP/ACY
Hydrogen bond Hydrophob.
Res (Chain) Atom Dist (Å) Res (Cha
Monomer A
Glu189 (A) OE1/N1 2.5 Ala120
OE2/N2 2.5 Ala121
Gly122
Asn231 (A) ND2/N7 3.1 Phe153
ND2/O6 3.0 Tyr188
Val205
Gly206
Met207
Leu241
Val246
Monomer B
Glu189 (B) OE1/N1 2.4 Ser36 (
OE2/N2 2.5 Ala120
Ala121
Asn231 OD1/N7 2.7 Phe153
Tyr188
Val205
Gly206
Met207
Monomer C
Glu189 (C) OE2/N2 2.6 Ala120
Ala121
Asn231 (C) OD1/N7 2.2 Gly122
ND2/O6 2.6 Tyr188
Gly206
Thr230 (C) OG1/N7 2.6 Met207
Val246
Distance cutoffs used for hydrogen bonding and hydrophobic interactions were 2.7e3.53.3. Interactions of MtPNP with ACY and PO4
The interactions between ACY and MtPNP were evaluated with
the Ligplot program [44], which revealed four intermolecular
hydrogen bonds between the ligand and the residues Glu189 and
Asn231, and hydrophobic contacts with other residues of the
binding pocket. All interactions are shown in Table 2. In addition,
we observed that PO4 binds beneath the inhibitor, in the active site,
to stabilize the oxocarbenium transition-state and orients the
nucleoside substrate [19]. Exceptionally in monomer A (Table 2),
the MtPNP residues involved in hydrogen bonds with PO4 are
provided from loop regions, excluding Ala120. Analysis of hydrogen
bonds showed that Arg88 and Ser208 interact with O1, while
Ala120 interacts with O4 (monomer B) and O1 (monomer C).
Although described in a previous work (MtPNP structure with
Immucillin [19]), there seems to be no interactions between PO4
and residues His90 and Ser36 in MtPNP:ACY.
The PO4 substrate interactions from MtPNP crystallopgraphic
structure were analyzed, and the PO4 hydrogen bond interactions
are shown in Table 2. As previously mentioned, the interactions
between PO4 and MtPNP do not follow the same pattern of inter-
actions in the monomers.
We also evaluated the effect of the PO4 substrate on drug-
inhibitor binding of ACY to MtPNP. However, it should be pointed
that, in the MtPNP:ACY:PO4 system, the total interaction energy
between the enzyme and the inhibitor was calculated in the
presence of PO4 in monomer A, and absence in the monomer B. As
shown in Fig. 4, the association of a single PO4 ion causes an
increase of approximately 50 kJ/mol until 5 ns of MD simulation. A
decrease of interaction energy occurs, suggesting that ACY is
moving away from the active binding site.ulations.
MtPNP/PO4
contact Hydrogen bond
in) Res (Chain) Atom Dist (Å)
(A) Ala120 (A) N/O2 3.1
(A)
(A) Tyr180 (A) OH/O4 3.4
(B)
(A) Met207 (A) N/O4 3.4
(A)
(A) Ser208 (A) OG/O1 2.8
(A)
(A)
(A)
B) Ser36(B) OG/O3 2.4
(B)
(B) Arg88 (B) NH1/O1 2.6
(C)
(B) Hi90 (B) NE2/O1 3.4
(B)
(B) Ala120 (B) N/O4 2.6
(B)
Ser208 (B) OG/O3 2.6
(C) Ser36(C) OG/O4 2.8
(C)
(C) Arg88 (C) NH1/O4 3.0
(C)
(C) His90 (C) NE2/O4 3.0
(C)
(C) Ala120 (C) N/O1 2.8
Ser208 (C) OG/O2 2.5
Å and 2.9e3.9 Å, respectively.
Fig. 4. Interaction energy between MtPNP and ACY. The black line represents the interaction energy between MtPNP and ACY of monomer A, and the gray line represents the
interaction energy between MtPNP and ACY of monomer B (in absence of PO4). The squares present the displacement of ACY away from the active site at 10 ns (green structure) MD
simulation (top left) and at 20 ns (orange structure) MD simulation (bottom right) on monomer A, where the reference is ACY crystallographic structure. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
R.A. Caceres et al. / Biochimie 94 (2012) 155e1651603.4. Differences between HsPNP and MtPNP in complex with ACY
In order to evaluate the possible differences in the PNP
structure from Homo sapiens and M. tuberculosis, the crystallo-
graphic structures were superposed (Fig. 5). The MtPNP:ACY:PO4
was used as reference against HsPNP:ACY (PDB: 1PWY [45]). The
water and PO4 were omitted and the RMSD average for Ca
superposition was 1.31 Å, at the purine binding site the RMSD
average for Ca was 0.51 Å (MtPNP: Ala120, Ala121, Gly122,
Glu189, and Asn231; and HsPNP: Ala116, Ala117, Gly118, Glu201,
and Asn243). The major differences in the secondary structures of
MtPNP and HsPNP are probably due to differences between theFig. 5. The Ca superposition of HsPNP:ACY (blue) against MtPNP:ACY:PO4 (red). The struct
shown in stereoview. (For interpretation of the references to colour in this ﬁgure legend, tlength of polypeptide chains, where HsPNP presents 21 amino
acids more than MtPNP.
3.5. Molecular dynamics simulations
The MD simulations of free MtPNP and MtPNP:ACY:PO4 ternary
complex structures were performed using SPC/E water model, as
previously described in section 2.3, and applying periodic boundary
conditions.
The stability of the previous simulations was examined by
conventional structural and geometrical analysis. Fig. 6 shows
the RMSD of the Ca atomic positions for the MtPNP andures are presented as ribbon diagram and the ACY molecule as stick. The structure is
he reader is referred to the web version of this article.)
Fig. 6. RMSD of unbound MtPNP (black line) and MtPNP:ACY:PO4 (red line) systems.
(For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
Fig. 8. Calculated B-factor of monomers which compose the unbound MtPNP (blue
line) and MtPNP:ACY:PO4 (red line). (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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during the ﬁrst 100 ps, the protein backbone RMSD average and
standard deviation over the 20 ns of the MtPNP system trajectory
was 2.4  0.2 Å and the MtPNP:ACY:PO4 system was 3.4  0.6 Å. It
can be seen that the MtPNP simulation has reached an equilibrated
state after 500 ps; however, the MtPNP:ACY:PO4 system reached
equilibrium after 15 ns.
The stability and the inﬂuence of ACY over the quaternary
structure during the MD simulations were assessed by the RG. RG
as a function of time is shown in Fig. 7A. The mean values of the RG
averaged over the period from 0 to 20 ns of each monomer were
determined, giving 27.9  1.2 Å and 28.3  1.6 Å for MtPNP and
MtPNP:ACY:PO4, respectively. Monomers A, B and C present an RG
of: 17.9  0.13 Å, 17.8  0.09 Å, and 17.6  0.07 Å, respectively
(Fig. 7B).Fig. 7. (A) Radius of gyration between unbound MtPNP (black line) and MtPNP:ACY:PO4 (
bounded to ACY and PO4 (black line), monomer B is bounded to ACY (red line), and monome
legend, the reader is referred to the web version of this article.)RG remains essentially constant after 200 ps for both systems,
suggesting that the molecular conformation was signiﬁcantly
preserved as a whole. This analysis suggests that RG centered on
the center of mass of the trimeric MtPNP remains essentially
constant, indicating that the monomers of MtPNP structure remain
in the trimeric state, which is the biological unit for MtPNP.
3.6. The role of Phe153 in MtPNP
As demonstrated in previous MD studies [8,46e48], Phe159
from HsPNP presents an important structural behavior, working
like a lid mechanism in the binding pocket of the adjacent subunit.
In M. tuberculosis, nevertheless, Phe153 does not seem to play the
same role. Fig. 8 shows that B-factor values are not affected by the
presence of ACY in the binding pocket as in HsPNP [8,48], thus
suggesting that Phe153 does not maintain any kind of interaction
with the active binding site making hydrophobic contact and,
therefore, no involvement in pep interactions with the basered line). (B) Radius of gyration between MtPNP:ACY:PO4 monomers. Monomer A is
r C in free form (blue line). (For interpretation of the references to colour in this ﬁgure
Table 3
Eigenvalues (EV) and cumulative eigenvalues (CV) of the covariance matrix resulting from unbound MtPNP and MtPNP:ACY:PO4 simulations.
Structure Eigenvector Monomer A Monomer B Monomer C Structure Eigenvector Monomer A Monomer B Monomer C
EVa CVb EV CV EV CV EV CV EV CV EV CV
MtPNP
unbound
1 68.09 24.52 136.66 37.24 47.97 20.96 MtPNP:ACY:PO4 1 90.10 26.81 120.40 29.09 48.83 40.76
2 38.16 38.26 24.94 44.03 21.93 30.54 2 39.29 38.21 41.86 39.20 16.69 27.56
3 12.64 42.81 17.39 48.77 10.34 35.05 3 25.00 45.65 38.21 48.43 13.88 33.39
4 11.44 46.94 13.65 42.49 9.61 39.25 4 16.68 50.62 16.87 52.51 13.22 38.95
5 9.54 50.37 11.20 55.54 8.02 42.76 5 13.64 54.67 14.21 55.95 10.38 43.32
6 7.53 53.08 9.05 58.00 7.22 45.91 6 9.88 57.61 13.42 59.19 6.78 46.17
7 5.79 55.17 8.16 60.23 6.52 48.76 7 8.17 60.05 11.41 61.94 6.59 48.94
8 5.42 57.12 7.00 62.13 5.10 50.99 8 6.51 61.98 8.12 63.91 5.59 51.29
9 4.56 58.76 6.07 63.79 4.46 52.93 9 6.29 63.86 6.99 65.59 4.96 53.38
10 4.16 60.26 5.85 65.38 3.94 54.65 10 5.20 64.40 6.29 67.11 4.79 55.39
a Eigenvalues of covariance matrix (A2).
b Cumulative sum values (%).
R.A. Caceres et al. / Biochimie 94 (2012) 155e165162moiety, as observed in other trimeric PNPs [5]. This is supported by
the data in Tables S1 and S2, where the interactions between the
protein and ACY were monitored along MD simulations and testi-
fying the displacement of ACY from the purine base binding site. In
fact, the role of Phe153 seems to be involved mainly in sugar
binding; more precisely, this residue lies close to position 50 of the
sugar group of the substrate. Nevertheless, the same behavior
herein observed was identiﬁed in MtPNP associated with Inosine
and Hypoxanthine [R.A. Caceres, L.F.S.M Timmers, R.G. Ducati, L.A.
Rosado, L.A. Basso, D.S. Santos, W.F. de Azevedo Jr., Combining
crystallographic, thermodynamic, and molecular dynamics studies
of M. tuberculosis purine nucleoside phosphorylase, unpublished
results].
3.7. Principal component analysis
Apart from conventional structural and geometrical analysis to
assess the stability of the simulations, PCA is utilized to identify
large concerted motions in MtPNP:ACY:PO4. We built theFig. 9. Displacement of the components of the ﬁrst eigenvectors for trimeric structures of
references to colour in this ﬁgure legend, the reader is referred to the web version of thiscovariance matrixes of the atomic ﬂuctuations in an MD trajectory,
in which the overall translation and rotation modes have been
removed. Elimination of the overall motion was done at each
simulation step, and the total removal of these irrelevant motions
was ensured by ﬁtting all the structures to the initial structure. It
has been shown that it is sufﬁcient to use only the Ca atomic
positions when building the covariance matrix [49]. The matrix is
built considering structures sampled every 0.5 ps from the
production run of the simulations. A total of 262 residues were
included in the analysis, and diagonalization of the covariance
matrix resulted in 786 eigenvectors.
Table 3 shows the contribution to the overall motion of the ﬁrst
10 eigenvectors of one singled-out simulation for each structure
and the contribution from each monomer in the protein. It can be
seen that the ﬁrst 10 eigenvectors describe a representative
percentage of the motions, 60.10% and 62.30% in average, for the
trimeric MtPNP and MtPNP:ACY:PO4, respectively.
The analysis by monomer of the unbound MtPNP simulation
has shown that the total positional ﬂuctuations described by theunbound MtPNP (black line) and MtPNP:ACY:PO4 (red line). (For interpretation of the
article.)
Fig. 10. The double-reciprocal plot reveals an ACY competitive inhibition pattern for
MtPNP with respect to Inosine, as the family of lines intersect on the y axis. Each curve
represents varied-ﬁxed levels of ACY as follows: (C) 0, (-) 32, and (+) 48 nM.
Fig. 12. Overall dissociation constant for MtPNP:ACY binary complex formation
monitoring changes in intrinsic protein ﬂuorescence.
R.A. Caceres et al. / Biochimie 94 (2012) 155e165 163ﬁrst 10 eigenvectors are 60.26%, 65.38%, and 54.65% for monomers
A, B, and C, respectively. The results of the ﬁrst eigenvectors alone
represent 24.52% (monomer A), 37.24% (monomer B), and 20.96%
(monomer C) of the total motion of the protein. For the
MtPNP:ACY:PO4 complex simulation, the analysis has shown that
the total positional ﬂuctuations described by the ﬁrst 10 eigen-
vectors are 64.40%, 67.11%, and 55.39% for monomers A, B, and C,
respectively. The results of the ﬁrst eigenvectors alone represent
26.81% (monomer A), 29.09% (monomer B), and 40.76% (monomer
C) of the total motion of the protein (Table 3). The signiﬁcant
ﬂuctuations of the ﬁrst eigenvector are shown in Fig. 9. The main
ﬂuctuations are presented for the regions formed by loops,
composed by Thr23-Val30, Gly35-Thr49, Ala55-Ala69, Arg88-
His102, Asp172-Leu175, Pro191-Leu200 (a-helix), and Asn231-
Ser253. However, when complexed with ACY, the regions
composed by Thr143-Ser161 and Pro184-Thr190 are localized in
the subunit interfaces, and seem to be affected by a decreasing of
ﬂuctuation, as would be expected. An interesting ﬁnding in the
ﬁrst eigenvector structure is the ﬂexibility of loops Pro184-Thr190
and Asn231-Ser243, which are involved in binding and releasing
events in the purine binding site.Fig. 11. MtPNP relative activity as a function of ACY concentration.3.8. Assessment of ACY upon MtPNP activity
Data from ACY inhibition studies were ﬁtted to a Line-
weavereBurk double-reciprocal plot (Fig. 10), and the results
demonstrate that ACY is a competitive inhibitor of MtPNP with
respect to Inosine, yielding a Ki value of 150  46 nM. A value of
41  3 mM was determined for ACY IC50 at near KM values for the
substrates for MtPNP using linear regression (Fig. 11).3.9. Equilibrium binding of ACY to MtPNP
The enhancement in intrinsic protein ﬂuorescence upon ACY
binding to MtPNP was sigmoidal (Fig. 12) and ﬁtting the data to
the Hill equation yielded values of 68  8 mM for K0 and 3.3  0.1
for n. This result shows that ACY binds to free MtPNP and it is in
good agreement with the low degree of cooperativity of ACY
binding.4. Conclusions
The resolution of the MtPNP structure in complex with ACY and
PO4 provided additional information for the structure-based drug
design initiatives, since there are very fewMtPNP structures solved
so far. In addition, as one dissects the MD results, it could be
observed that Phe153 from MtPNP does not exhibit the same
conformational behavior if compared to Phe159 from HsPNP. The
Similarity Ensemble Approach (SEA) [50] demonstrated to be very
useful tool. It was used aiming to verify the potential inhibition of
ACY. The SEA provided an e-value of 1.12  10122 and a maximum
Tanimoto coefﬁcient of 56%, giving indications that ACY could be an
inhibitor. Probably, the result provided by the server was due to the
purine moiety similarity between ACY and Immucillin, a known
potential and established PNP inhibitor. Therewithal, this consid-
erable inhibition may provide some clues, as ACY could be helpful
to the development of a potential inhibitor; structure-based drug
design initiatives should be carried out aiming at structural modi-
ﬁcations and, consequently, increasing the inhibition. In addition,
the inhibition data provided by ACY in complex with MtPNP is
essential, since such information about inhibitors are sparse and
pivotal in the development of speciﬁc empirical scoring functions
and QSAR models.
R.A. Caceres et al. / Biochimie 94 (2012) 155e1651644.1. Deposit
The atomic coordinates and structure factors for the MtPNP:A-
CY:PO4 structure have been deposited at the Protein Data Bank,
access code:3IX2.
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